UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

Amele, S; Sandri, AK; Rodger, A; Vandekerckhove, L; Benfield, T; Milinkovic, A; Duvivier, C; ... Peters, L; + view all (2022) HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. HIV Medicine , 23 (6) pp. 684-692. 10.1111/hiv.13212. Green open access

[thumbnail of Cozzi-Lepri_HCV reinfection after HCV therapy among HIV:HCV-coinfected individuals in Europe_AAM.pdf]
Preview
Text
Cozzi-Lepri_HCV reinfection after HCV therapy among HIV:HCV-coinfected individuals in Europe_AAM.pdf - Accepted Version

Download (220kB) | Preview

Abstract

OBJECTIVES: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained virological response (SVR) in HIV/HCV-coinfected individuals in Europe. METHODS: Factors associated with odds of reinfection by 2 years after SVR in EuroSIDA participants with one or more HCV-RNA test and 2 years follow-up were assessed using logistic regression. RESULTS: Overall, 1022 individuals were included. The median age was 50 (interquartile range: 43–54 years), and most were male (78%), injection drug users (52%), and received interferon (IFN)-free DAAs (62%). By 24 months, 75 [7.3%, 95% confidence interval (CI): 5.7–8.9%] individuals were reinfected. Among individuals treated prior to 2014, 16.1% were reinfected compared with 4.2% and 8.3%, respectively, among those treated during or after 2014 with IFN-free and IFN-based therapy. After adjustment, individuals who had started treatment during or after 2014 with IFN-free or IFN-based therapy had significantly lower odds of reinfection (adjusted odds ratio = 0.21, 95% CI: 0.11–0.38; 0.43, 95% CI: 0.22–0.83) compared with those who had received therapy before 2014. There were no significant differences in odds of reinfection according to age, gender, European region, HIV transmission risk group or liver fibrosis. CONCLUSIONS: Among HIV/HCV-coinfected individuals in Europe, 7.3% were reinfected with HCV within 24 months of achieving SVR, with evidence suggesting that this is decreasing over time and with use of newer HCV regimens. Harm reduction to reduce reinfection and surveillance to detect early reinfection with an offer of treatment are essential to eliminate HCV.

Type: Article
Title: HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/hiv.13212
Publisher version: https://doi.org/10.1111/hiv.13212
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: direct-acting antivirals, HCV, HIV, interferon, reinfection
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health
URI: https://discovery.ucl.ac.uk/id/eprint/10141557
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item